Structure Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GPCR research report →
Companystructuretx.com
Structure Therapeutics Inc. , a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
- CEO
- Raymond C. Stevens
- IPO
- 2023
- Employees
- 163
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $2.12B
- P/E
- -15.66
- P/S
- 0.00
- P/B
- 1.85
- EV/EBITDA
- -9.52
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -15.14%
- ROIC
- -14.44%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-141,202,000 · -15.24%
- EPS
- $-2.40 · -2.56%
- Op Income
- $-287,567,533
- FCF YoY
- -91.49%
Performance & Tape
- 52W High
- $94.90
- 52W Low
- $15.80
- 50D MA
- $47.44
- 200D MA
- $45.92
- Beta
- -1.39
- Avg Volume
- 921.40K
Get TickerSpark's AI analysis on GPCR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 15, 26 | Lang Matthew | other | 223,776 |
| Apr 15, 26 | Lang Matthew | other | 184,614 |
| Apr 15, 26 | Lang Matthew | other | 0 |
| Apr 14, 26 | FMR LLC | sell | 16,085 |
| Apr 14, 26 | FMR LLC | sell | 1,367 |
| Mar 19, 26 | Hall Ashley | other | 47,706 |
| Mar 19, 26 | Hall Ashley | other | 59,073 |
| Mar 19, 26 | Coll Crespo Blas | other | 75,897 |
| Mar 19, 26 | Coll Crespo Blas | other | 93,984 |
| Mar 19, 26 | Ma Yingli | other | 32,526 |
Our GPCR Coverage
We haven't published any research on GPCR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GPCR Report →